2026 Price Guide,BPD is a peptide-based PROTAC

The field of drug development is undergoing a significant transformation with the emergence of peptide PROTAC technology. These innovative molecules, also known as proteolysis-targeting chimeras (PROTACs), represent a new type of treatment that can induce the dynamic degradation of intracellular or nuclear proteins of interest (POI). Unlike traditional drugs that merely inhibit protein function, peptide-based PROTACs actively recruit the cell's natural protein degradation machinery, the Ubiquitin-Proteasome System (UPS), to eliminate target proteins. This approach offers a powerful new strategy for tackling diseases previously considered undruggable.

At its core, a peptide PROTAC is a bifunctional molecule. It typically comprises a target protein binding peptide (TBP), a linker peptide (LP), and a moiety that recruits an E3 ubiquitin ligase. The TBP specifically binds to the aberrant or disease-causing protein, while the E3 ligase ligand brings the ligase into close proximity. This proximity tagging by the E3 ligase then marks the target protein for ubiquitination, a process that flags it for degradation by the proteasome. This mechanism is a departure from traditional drug design, where peptide drugs often rely on auxiliary action mechanisms or synergetic therapeutic effects.

The advantages of peptide PROTAC technology over conventional peptide drugs are substantial. Research indicates that peptide PROTAC drugs present notable advantages in drug design, including heightened specificity, enhanced efficacy, and reduced toxicity. This heightened specificity is crucial for minimizing off-target effects and improving patient safety. Furthermore, the inherent biodegradability and flexibility in structural design offered by peptides contribute to their therapeutic potential. For example, a cyclic peptide PROTAC targeting palmitoyltransferase has shown stable and improved anti-PD-L1 activity, demonstrating the versatility of this approach.

The development of peptide-based PROTACs is gaining significant traction, with companies offering professional peptide-based PROTAC development services, including molecular structure design, validation, and optimization. This indicates a growing industry focus on harnessing this technology for therapeutic breakthroughs. The ability of peptide PROTACs to target a wider range of proteins, including those not amenable to small molecule inhibition, is a key driver of this interest. This is particularly relevant for diseases driven by mutated or overexpressed proteins, where traditional inhibitors may be ineffective.

Several promising applications of peptide PROTACs are emerging. For instance, a peptide-based PROTAC designed to degrade BRCA2 has demonstrated the ability to selectively accumulate in tumor cells and reduce homologous recombination, a critical process for DNA repair in cancer. Another example is a PROTAC peptide that induces durable β-catenin degradation, suppressing Wnt-dependent intestinal cancer, highlighting the potential of PROTAC peptides in oncological applications. Studies have also explored peptide-based PROTACs targeting FOXM1, a protein implicated in various cancers, to suppress tumor growth.

Compared to their small-molecule counterparts, peptide PROTACs offer unique benefits. Their larger size allows for the potential of multitargeting, and their biodegradability can lead to reduced systemic toxicity. Moreover, the inherent flexibility in peptide design allows for the exploration of novel structural modalities, such as peptide-based self-assembling Nano-PROTACs, which can form ordered nanostructures *in situ* within tumors, enhancing targeted delivery and efficacy. Peptide PROTAC is the earliest form of PROTACs, laying the groundwork for subsequent advancements.

The journey of peptide PROTAC development is ongoing, with ongoing research focused on overcoming current challenges and exploring future directions. The ability to design and synthesize novel fully peptide-based PROTACs, such as FPP29, which has demonstrated significant toxicity and inhibitory effects, underscores the rapid progress in this area. As PROTAC technology continues to mature, it is poised to revolutionize targeted protein degradation, expanding the druggable proteome and paving the way for more potent and selective therapies for a wide spectrum of diseases. The exploration of peptide PROTACs is a testament to the innovative spirit driving modern medicine, offering hope for more effective treatments and improved patient outcomes.